Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Seema A. Bhat, MD, a hematologist specializing in chronic lymphocytic leukemia (CLL) at The Ohio State University Comprehensive Cancer Center–James, discusses the rationale to evaluate acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

The international phase 3 ASCEND trial randomized patients with previously treated CLL to receive acalabrutinib monotherapy or rituximab (Rituxan) in combination with idelalisib (Zydelig) or bendamustine.

Acalabrutinib is a next-generation BTK inhibitor that, like ibrutinib (Imbruvica), is covalently binding, Bhat explains.

Moreover, in November 2019, acalabrutinib was granted regulatory approval by the FDA for the treatment of patients with CLL or small lymphocytic lymphoma based on findings from the ASCEND trial, as well as results from the phase 3 ELEVATE-TN trial, concludes Bhat.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Hannah Choe, MD, an expert on GVHD